Axogen Announces Appointment of Jesse Bishop as Vice President of Regulatory Affairs and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Axogen (NASDAQ: AXGN), a leader in surgical solutions for peripheral nerve injuries, has appointed Jesse Bishop as Vice President of Regulatory Affairs. Reporting to CEO Michael Dale, Bishop will lead domestic and international regulatory strategies for new product development, market approval, and regulatory initiatives.
Bishop brings over 13 years of leadership experience in regulatory strategy and CMC, CGMP manufacture of cell and gene therapies, having worked at companies including Thermo Fisher Scientific, RGI Medical Manufacturing, and Ology Bioservices. He served in the U.S. Army Special Operations as a Ranger Team Leader and Combat Medic and holds master's degrees in medical sciences and business administration from the University of Florida.
As part of his employment package starting February 3, 2025, Bishop will receive an inducement grant of 45,000 Restricted Stock Units (RSUs) on March 3, 2025. The RSUs will vest over 4 years, with 50% vesting after two years and 25% vesting annually for the following two years.
Axogen (NASDAQ: AXGN), leader nelle soluzioni chirurgiche per lesioni dei nervi periferici, ha nominato Jesse Bishop Vice Presidente degli Affari Regolatori. Riportando al CEO Michael Dale, Bishop guiderà le strategie regolatorie nazionali e internazionali per lo sviluppo di nuovi prodotti, approvazione al mercato e iniziative regolatorie.
Bishop porta con sé oltre 13 anni di esperienza nella leadership in strategie regolatorie e nella produzione CMC, CGMP di terapie cellulari e geniche, avendo lavorato in aziende come Thermo Fisher Scientific, RGI Medical Manufacturing e Ology Bioservices. Ha servito nelle Operazioni Speciali dell'Esercito degli Stati Uniti come Team Leader Ranger e Medico di Combattimento e possiede master in scienze mediche e amministrazione aziendale presso l'Università della Florida.
Come parte del suo pacchetto di assunzione a partire dal 3 febbraio 2025, Bishop riceverà un premio di incentivazione di 45.000 Unità di Azioni Riservate (RSUs) il 3 marzo 2025. Le RSUs matureranno in 4 anni, con il 50% che matura dopo due anni e il 25% che matura annualmente per i due anni successivi.
Axogen (NASDAQ: AXGN), líder en soluciones quirúrgicas para lesiones de nervios periféricos, ha nombrado a Jesse Bishop como Vicepresidente de Asuntos Regulatorios. Reportando al CEO Michael Dale, Bishop dirigirá las estrategias regulatorias nacionales e internacionales para el desarrollo de nuevos productos, aprobación en el mercado e iniciativas regulatorias.
Bishop aporta más de 13 años de experiencia en liderazgo en estrategias regulatorias y en la fabricación CMC, CGMP de terapias celulares y génicas, habiendo trabajado en empresas como Thermo Fisher Scientific, RGI Medical Manufacturing y Ology Bioservices. Sirvió en las Operaciones Especiales del Ejército de EE. UU. como Líder de Equipo Ranger y Medic de Combate, y posee títulos de maestría en ciencias médicas y administración de empresas de la Universidad de Florida.
Como parte de su paquete de empleo a partir del 3 de febrero de 2025, Bishop recibirá una concesión de incentivo de 45.000 Unidades de Acción Restringida (RSUs) el 3 de marzo de 2025. Las RSUs se otorgarán en un período de 4 años, con el 50% otorgándose después de dos años y el 25% anualmente durante los dos años siguientes.
Axogen (NASDAQ: AXGN)는 말초 신경 손상을 위한 외과 솔루션의 선두주자로서 Jesse Bishop를 규제 담당 부사장으로 임명했습니다. CEO Michael Dale에게 보고하는 Bishop은 새로운 제품 개발, 시장 승인 및 규제 이니셔티브를 위한 국내 및 국제 규제 전략을 이끌 것입니다.
Bishop은 Thermo Fisher Scientific, RGI Medical Manufacturing 및 Ology Bioservices와 같은 회사에서 근무하며 규제 전략 및 CMC, CGMP 세포 및 유전자 치료 제조에서 13년 이상의 리더십 경험을 가지고 있습니다. 그는 미 육군 특수작전에서 레인저 팀 리더 및 전투 의무병으로 복무했으며, 플로리다 대학교에서 의학 및 경영학 석사 학위를 취득했습니다.
2025년 2월 3일부터 그의 고용 패키지의 일환으로, Bishop은 2025년 3월 3일에 45,000개의 제한 주식 단위(RSUs) 유인 보상 지급을 받을 것입니다. RSUs는 4년 동안 분할 지급되며, 2년 후 50%가 확정되고, 이후 2년간 매년 25%씩 분할 지급됩니다.
Axogen (NASDAQ: AXGN), un leader dans les solutions chirurgicales pour les blessures des nerfs périphériques, a nommé Jesse Bishop au poste de vice-président des affaires réglementaires. Relevant du PDG Michael Dale, Bishop dirigera les stratégies réglementaires nationales et internationales pour le développement de nouveaux produits, l'approbation sur le marché et les initiatives réglementaires.
Bishop apporte plus de 13 ans d'expérience en leadership dans la stratégie réglementaire et la fabrication CMC, CGMP de thérapies cellulaires et géniques, ayant travaillé pour des entreprises telles que Thermo Fisher Scientific, RGI Medical Manufacturing et Ology Bioservices. Il a servi dans les opérations spéciales de l'armée américaine en tant que leader d'équipe Rangers et médecin de combat, et possède des masters en sciences médicales et en administration des affaires de l'Université de Floride.
Dans le cadre de son package d'emploi à compter du 3 février 2025, Bishop recevra une subvention d'incitation de 45 000 unités d'actions restreintes (RSUs) le 3 mars 2025. Les RSUs se libéreront sur une période de 4 ans, avec 50 % se libérant après deux ans et 25 % se libérant annuellement pendant les deux années suivantes.
Axogen (NASDAQ: AXGN), ein führendes Unternehmen für chirurgische Lösungen bei Verletzungen peripherer Nerven, hat Jesse Bishop zum Vice President für Regulierungsangelegenheiten ernannt. Bishop wird an CEO Michael Dale berichten und die nationalen und internationalen Regulierungsstrategien für die Entwicklung neuer Produkte, Marktgenehmigungen und regulatorische Initiativen leiten.
Bishop bringt über 13 Jahre Führungserfahrung in der Regulierungsstrategie sowie in der CMC-, CGMP-Herstellung von Zell- und Gentherapien mit und hat bei Unternehmen wie Thermo Fisher Scientific, RGI Medical Manufacturing und Ology Bioservices gearbeitet. Er diente in den US-Army Special Operations als Ranger-Teamleiter und Sanitäter und hat einen Masterabschluss in medizinischen Wissenschaften und Betriebswirtschaft von der University of Florida.
Als Teil seines Beschäftigungspakets, das am 3. Februar 2025 beginnt, erhält Bishop am 3. März 2025 eine Anreizzulage in Höhe von 45.000 Restricted Stock Units (RSUs). Diese RSUs werden über 4 Jahre endfällig, wobei 50 % nach zwei Jahren und 25 % jährlich in den folgenden zwei Jahren endfällig werden.
- Strategic hire with extensive regulatory experience in biologics and medical devices
- Structured RSU compensation package aligns executive interests with long-term shareholder value
- 45,000 RSU grant represents potential shareholder dilution
ALACHUA, Fla. and TAMPA, Fla., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced the appointment of Jesse Bishop as Vice President of Regulatory Affairs.
Mr. Bishop will report to Michael Dale, President, and Chief Executive Officer, and will lead the development and execution of domestic and international regulatory strategies to advance company objectives related to new product development, market approval, market development and other regulatory initiatives.
Mr. Bishop will oversee all facets of Axogen’s regulatory affairs, maintenance of Axogen product registrations, licenses, accreditations and in general all related interactions and relationships with regulatory agencies and associated stakeholders. Additionally, Mr. Bishop will be responsible for working on development of regulatory policy with external groups such as Alliance for Regenerative Medicine (ARM), American Association of Tissue Banks (AATB) and others.
Mr. Bishop brings extensive experience in leading regulatory strategy and CMC, CGMP manufacture of cell and gene therapies, biologics/vaccines, medical devices and combination products. Mr. Bishop has over 13 years of leadership experience in regulatory strategy, planning and execution in companies such as Thermo Fisher Scientific – Viral Vector Services, RGI Medical Manufacturing, Ology Bioservices and Lacerta Therapeutics. He also served in the military as a Ranger Team Leader and Combat Medic within U.S. Army Special Operations.
Mr. Bishop earned his master’s in medical sciences and business administration from the University of Florida.
“We are pleased to welcome Jesse to the Axogen team," said Michael Dale, Chief Executive Officer, and Director, Axogen. "His extensive experience in regulatory strategy and deep understanding of the biologics and medical device sectors will be valuable as we continue to advance our regulatory initiatives and expand our product portfolio.”
Jesse Bishop, Vice President of Regulatory Affairs, said: “I am honored to join Axogen and contribute to advancing the regulatory pathway for peripheral nerve repair technologies."
Notice of Issuance of Inducement Grant
In connection with the commencement of his employment on February 3, 2025, and as a material inducement of employment, Mr. Bishop will be awarded an equity grant on March 3, 2025, consisting of non-qualified equity grant in the form of Restricted Stock Units (RSU) for the grant of 45,000 shares of Axogen, Inc. common stock. The shares representing the RSUs are subject to vesting over 4 years, with
About Axogen
Axogen (AXGN) is the leading Company focused specifically on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. Axogen employees are passionate about helping to restore peripheral nerve function and quality of life to patients with physical damage or transection to peripheral nerves by providing innovative, clinically proven, and economically effective repair solutions for surgeons and health care providers. Peripheral nerves provide the pathways for both motor and sensory signals throughout the body. Every day, people suffer traumatic injuries or undergo surgical procedures that impact the function of their peripheral nerves. Physical damage to a peripheral nerve, or the inability to properly reconnect peripheral nerves, can result in the loss of muscle or organ function, the loss of sensory feeling, or the initiation of pain.
Axogen's platform for peripheral nerve repair features a comprehensive portfolio of products that are used across two primary application categories: scheduled, non-trauma procedures and emergent trauma procedures. Scheduled procedures are generally characterized as those where a patient is seeking relief from conditions caused by a nerve defect or surgical procedure. These procedures include providing sensation for women seeking breast reconstruction following a mastectomy, nerve reconstruction following the surgical removal of painful neuromas, oral and maxillofacial procedures, and nerve decompression. Emergent procedures are generally characterized as procedures resulting from injuries that initially present in an ER. These procedures are typically referred to and completed by a specialist either immediately or within a few days following the initial injury.
Axogen’s product portfolio includes Avance® Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; Axoguard Nerve Connector®, a porcine submucosa ECM coaptation aid for tensionless repair of severed peripheral nerves; Axoguard Nerve Protector®, a porcine submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments; Axoguard HA+ Nerve Protector™, a porcine submucosa ECM base layer coated with a proprietary hyaluronate-alginate gel, a next-generation technology designed to provide short- and long-term protection for peripheral nerve injuries; and Axoguard Nerve Cap®, a porcine submucosa ECM product used to protect a peripheral nerve end and separate the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma. The Axogen portfolio of products is available in the United States, Canada, Germany, the United Kingdom, Spain, South Korea, and several other countries.
Investor Contact:
Axogen, Inc.
InvestorRelations@axogeninc.com
